Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia
Open Access
- 1 May 2020
- journal article
- review article
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 12, 107-128
Abstract
Acute myeloid leukemia (AML) is a molecularly complex disease with multiple aberrant genetic pathways involved in its pathogenesis. Approximately one-third to one-half of patients with AML would relapse, and no standard therapy is established for relapsing and/or refractory AML (RR-AML) yet. It is unlikely that blockage of only one specific pathway will lead to prolonged remissions and cures in all fractions of the AML patients population. Nowadays, novel therapeutic agents with rational combination are being recognized which improve the cure rate for relapsed AML. These drugs and their metabolites impart unique properties in the interaction with each of the intracellular targets and metabolic enzymes whereby resulting in unique clinical activity. To date, most of the combinations have used a targeted agent combined with standard agents such as anthracyclines, cytarabine, or hypomethylating agents to improve the outcome. Rational combinations of DNA damage-inducing therapies with DNA methyltransferase and histone deacetylase inhibitors synergistically enhance the DNA damage, growth inhibition and apoptosis of myeloid cells. This review makes a thorough look at current antineoplastic agents for AML with emphasis on its genetics and molecular mechanisms of action and the role of combination regimens.Keywords
This publication has 34 references indexed in Scilit:
- New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic SyndromeHematology-American Society Hematology Education Program, 2011
- Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimensLeukemia Research, 2011
- Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of CancerFuture Oncology, 2011
- HDACi - going through the mechanismsFrontiers in Bioscience-Landmark, 2011
- Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of CancerChemical Reviews, 2009
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cellsLeukemia, 2009
- Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndromeLeukemia & Lymphoma, 2009
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid NeoplasmsCancer Research, 2006
- De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivoBlood, 2002